Chief Financial Officer · Adaptimmune Therapeutics PLC (ADAP)

Gavin Wood

FY2023 is the first fiscal year CompBrief holds for Gavin Wood as a named executive officer of Adaptimmune Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,171,239

Salary $441,402Stock awards $0

5th of 6 named executive officers at Adaptimmune Therapeutics by FY2023 total.

6 named officers on file for Adaptimmune Therapeutics, FY2023

Gavin Wood’s pay file — $29

  • 1 fiscal year of pay, line by line
  • ADAP’s disclosed peer group of 28 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Adaptimmune Therapeutics’s whole pay program stands against its peers

  • Adaptimmune Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on ADAP→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 11, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Gavin Wood’s full pay file as a PDF — free

More than this page: up to 10 years of Gavin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Gavin Wood compensation by year

Adaptimmune Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Adaptimmune Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$441,402
Bonus$0
Stock awards$0
Option awards$504,895
Non-equity incentive$188,700
Pension and deferred compensation$0
All other$36,242
Total$1,171,239

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Adaptimmune Therapeutics PLC DEF 14A filed April 11, 2024, accession 0001104659-24-046093, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Adaptimmune Therapeutics PLC filed document, accession 0001104659-24-046093. Every figure is read from that document and cited to the page and table it appears in. Filed April 11, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option208,440—$0.46
Option141,250—$0.00
Option121,356—$0.00
Option235,692—$0.00
Option1,407,072—$0.33
Option314,256—$0.00
Option294,346—$0.97
Option193,728—$0.00
Option732,894—$0.56

Per the Outstanding Equity Awards at Fiscal Year-End table in Adaptimmune Therapeutics PLC's FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1 Form 4 line since the FY2023 proxy (filed April 11, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-09-02Sale—96,000$0.010

The 1 most recent of 1 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Adaptimmune Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Adrian RawcliffeChief Executive Officer$2,774,041
William BertrandChief Operating Officer$1,215,100
Helen Tayton-MartinChief Business & Strategy Officer$1,183,352
Elliot NorryChief Medical Officer$1,180,968
Gavin Wood · this pageChief Financial Officer$1,171,239
Cintia PiccinaChief Commercial Officer$992,342

The full Adaptimmune Therapeutics compensation record

free company brief

This page is one person within Adaptimmune Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Adaptimmune Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Adaptimmune Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Gavin Wood's compensation dossier · One-time report. No refunds.